Health
Novo’s Saxenda Helped Kids as Young as Six Lose Weight in Trial
- Novo has submitted trial data to US, European drug regulators
- Doctors call for more study of drug’s long-term impact on kids
This article is for subscribers only.
Novo Nordisk A/S’s older weight-loss drug, Saxenda, helped children lose weight in a study, opening up the possibility of powerful obesity medications being prescribed to grade-school-aged kids.
Children with obesity aged 6 through 11 who got a Saxenda shot daily for 56 weeks saw their body mass index, or BMI, decline by an average of 5.8% in the study, while those who got a placebo experienced an increase of 1.6%, researchers said on Wednesday at the European Association for the Study of Diabetes meeting in Madrid. Side effects were in line with what’s been seen in adults, the researchers said. Novo funded the trial.